Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2021-09-13 , DOI: 10.1111/dom.14548
Juan P. Frías ₁ , Jill Maaske ₂ , Lisa Suchower ₃ , Lars Johansson ₄ , Paul D. Hockings _{4,

5} , Nayyar Iqbal ₂ , John P. H. Wilding ₆

Affiliation

To report the results of a 104-week extension to a 52-week study in which dapagliflozin plus saxagliptin (DAPA+SAXA) improved glycaemic control, liver fat and metabolic variables compared with glimepiride (GLIM) in participants with type 2 diabetes (T2D) receiving background metformin.

中文翻译：

达格列净联合沙格列汀对比格列美脲对 2 型糖尿病患者二甲双胍背景的长期影响：104 周延长至 52 周随机、3 期研究和肝脏脂肪 MRI 子研究的结果

报告将 104 周延长至 52 周研究的结果，在该研究中，与格列美脲 (GLIM) 相比，达格列净加沙格列汀 (DAPA+SAXA) 改善了 2 型糖尿病 (T2D) 参与者的血糖控制、肝脏脂肪和代谢变量接受背景二甲双胍。

更新日期：2021-09-13

点击分享查看原文

点击收藏

阅读更多本刊最新论文